Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain

NCT02065349 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.

NCT NCT02065349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02065349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain
Lead sponsor
Astellas Pharma Europe B.V.
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2014
Completion date
February 13, 2015
Enrollment
132 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic pain, painful diabetic peripheral neuropathy (pdpn), post-herpetic neuralgia (phn)